Cardinal Health, Inc. (CAH)

NYQ – Цена в реальном времени. Валюта: USD

237.92

+3.17 (1.35%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

238.00

+0.08 (0.03%)

После закрытия: Jun 26, 2026, 8:00 PM EDT

15.06.2026

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone Nearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugs Findings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITY SAN DIEGO, June 15, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 11β‑hydroxylase deficiency. This subtype was not previously studied in clinical trials of CRENESSITY® (crinecerfont) and is the second most common form of classic CAH after 21-hydroxylase deficiency, accounting for approximately 5% of cases.

12.06.2026

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

01.06.2026

Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in Cardinal (CAH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

01.06.2026

Here's Why Cardinal Health (CAH) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

27.05.2026

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

CAH and COR are betting big on specialty pharma, but Cardinal Health???s stronger growth, raised outlook, and broader expansion may set it apart.

27.05.2026

Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

27.05.2026

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Видео

03.11.2025

Neutral

Cardinal Health CEO says Obamacare subsidies extension under review 'every single day'

Пресс-релизы

15.06.2026

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

05.05.2026

Cardinal Health Board of Directors Approves Quarterly Dividend

DUBLIN, Ohio, May 5, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) announced today that its Board of Directors approved an increase to its quarterly dividend to $0.5158 per share, out of the Company's capital surplus. The dividend will be payable on July 15, 2026 to shareholders of record at the close of business on July 1, 2026.

30.04.2026

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Revenue increased 11% to $60.9 billion GAAP 1 operating earnings decreased 30% to $509 million; GAAP diluted EPS decreased 20% to $1.69 Non-GAAP operating earnings increased 18% to $956 million; non-GAAP diluted EPS increased 35% to $3.17 Cardinal Health raises and narrows fiscal year 2026 non-GAAP EPS guidance2 to $10.70 to $10.80 Cardinal Health reduces debt and completes additional $250 million share repurchase, bringing FY26 repurchase total to $1.0 billion DUBLIN, Ohio, April 30, 2026 /PRNewswire/ -- Cardinal Health (NYSE: CAH) today reported third quarter fiscal year 2026 revenues of $60.9 billion, an increase of 11% from the third quarter of fiscal year 2025. Third quarter GAAP operating earnings decreased 30% to $509 million and GAAP diluted earnings per share (EPS) decreased 20% to $1.69, reflecting a $184 million pre-tax goodwill impairment in the company's Navista & ION reporting unit primarily due to changes in the risk profile of the business plans resulting in an increase in the discount rate.

14.04.2026

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Research confirms advanced therapies are moving beyond inpatient hospitals, with providers increasingly supporting partnerships that bring life-changing treatments closer to patients' homes. DUBLIN, Ohio, April 14, 2026 /PRNewswire/ -- Today, Cardinal Health (NYSE: CAH) released its 2026 Advanced Therapies Report: Perspectives on Community Expansion, offering new insights into how the expanding advanced therapy pipeline is reshaping sites of care.

Cardinal Health, Inc. (CAH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cardinal Health, Inc. (CAH)

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know

Here's Why Cardinal Health (CAH) is a Strong Value Stock

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Видео

Пресс-релизы

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know

Here's Why Cardinal Health (CAH) is a Strong Value Stock

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Видео

Пресс-релизы

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Search stocks

Cardinal Health, Inc. (CAH)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Cardinal Health, Inc. (CAH)

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know

Here's Why Cardinal Health (CAH) is a Strong Value Stock

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Видео

Пресс-релизы

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Is Cardinal Health (CAH) Stock Undervalued Right Now?

Wall Street Analysts Predict a 25.75% Upside in Cardinal (CAH): Here's What You Should Know

Here's Why Cardinal Health (CAH) is a Strong Value Stock

CAH vs. COR: Which Healthcare Distributor Stock Is the Better Buy?

Why Cardinal Health (CAH) is a Top Growth Stock for the Long-Term

Is Cardinal Health (CAH) a Great Value Stock Right Now?

Видео

Пресс-релизы

Neurocrine Biosciences Presents First Retrospective Case Series of CRENESSITY® (crinecerfont) in Patients with Classic Congenital Adrenal Hyperplasia Due to 11β‑Hydroxylase Deficiency at ENDO 2026

Cardinal Health Board of Directors Approves Quarterly Dividend

Cardinal Health Reports Third Quarter Fiscal Year 2026 Results and Raises Outlook

Cardinal Health report highlights growing momentum to expand advanced therapies into community care settings